Coya Therapeutics Inc
COYA
Company Profile
Business description
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells (Tregs). The company's initial development programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases with high unmet medical needs.
Contact
5850 San Felipe Street
Suite 500
HoustonTX77057
USAT: +1 800 587-8170
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
8
Stocks News & Analysis
stocks
Jet fuel price spike weighing on Australian airline profits
Fuel volatility can lead to short-term earnings swings but all players bear the cost almost equally.
stocks
US utilities stocks keep rallying as investors bet on power demand growth
Rising electricity demand from data centers supports earnings growth, but Morningstar analysts say the sector looks less attractive after a sharp rally.
stocks
What did Morningstar subscribers buy and sell during March?
How the most traded shares in March stack up against our analysts views.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,181.10 | 29.10 | -0.32% |
| CAC 40 | 8,276.95 | 50.91 | -0.61% |
| DAX 40 | 24,063.59 | 19.37 | 0.08% |
| Dow JONES (US) | 48,535.99 | 317.74 | 0.66% |
| FTSE 100 | 10,615.17 | 6.11 | 0.06% |
| HKSE | 25,947.32 | 75.00 | 0.29% |
| NASDAQ | 23,639.08 | 455.35 | 1.96% |
| Nikkei 225 | 58,134.24 | 256.85 | 0.44% |
| NZX 50 Index | 13,076.58 | 59.32 | 0.46% |
| S&P 500 | 6,967.38 | 81.14 | 1.18% |
| S&P/ASX 200 | 8,978.70 | 32.70 | -0.36% |
| SSE Composite Index | 4,027.21 | 0.58 | 0.01% |